Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Scott Kinlay։ Cancer and Adverse Outcomes Over 5 Years After Coronary Stenting and Optimal DAPT Duration
Scott Kinlay, Ramael Ohiomoba and Edwin Mandieka
Feb 3, 2026, 16:23

Scott Kinlay։ Cancer and Adverse Outcomes Over 5 Years After Coronary Stenting and Optimal DAPT Duration

Scott Kinlay, Chief of Cardiology at VA Boston Healthcare System and Associate Professor of Medicine at Harvard Medical School, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

”Just published: Ramael Ohiomoba and Edwin Mandieka’s paper examines the relationship of cancer to adverse outcomes over 5 years after coronary stenting, as well as the optimal duration DAPT.

Key findings were that cancer patients have higher rates of myocardial infarction and major bleeding after PCI compared to non-cancer patients. The analysis also supports a similar duration of DAPT after PCI in cancer patients as non-cancer patients.”

Title: Relationship of cancer and dual antiplatelet duration to long-term risk of ischaemic and bleeding outcomes after percutaneous coronary intervention

Authors: Ramael Ohiomoba, Edwin Mandieka, Melissa M Young, David R Gagnon, Scott Kinlay

Read the Full Article on European Heart Journal.

Scott Kinlay։ Cancer and Adverse Outcomes Over 5 Years After Coronary Stenting and Optimal DAPT Duration

Stay updated on all scientific advances with Hemostasis Today.

 

DAPT David R Gagnon Edwin Mandieka Health Hematology Hemostasis Hemostasis Today Medicine Melissa M Young Ramael Ohiomoba Scott Kinlay
NewsFeed